Resources from the same session
LBA16 - KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Presenter: Hope Rugo
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Presenter: Gabriel Hortobagyi
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA15 - Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
Presenter: Cristina Saura Manich
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA15
Presenter: Barbara Pistilli
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Barbara Pistilli
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Gonzalo Gomez-Abuin
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Slides
Webcast